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Abstract
Background: There is conflicting information as to whether antiretroviral drugs with better central nervous system
(CNS) penetration (neuroHAART) assist in improving neurocognitive function and suppressing cerebrospinal fluid
(CSF) HIV RNA. The current review aims to better synthesise existing literature by using an innovative two-phase
review approach (qualitative and quantitative) to overcome methodological differences between studies.
Methods: Sixteen studies, all observational, were identified using a standard citation search. They fulfilled the
following inclusion criteria: conducted in the HAART era; sample size > 10; treatment effect involved more than
one antiretroviral and none had a retrospective design. The qualitative phase of review of these studies consisted
of (i) a blind assessment rating studies on features such as sample size, statistical methods and definitions of
neuroHAART, and (ii) a non-blind assessment of the sensitivity of the neuropsychological methods to HIV-
associated neurocognitive disorder (HAND). During quantitative evaluation we assessed the statistical power of
studies, which achieved a high rating in the qualitative analysis. The objective of the power analysis was to
determine the studies ability to assess their proposed research aims.
Results: After studies with at least three limitations were excluded in the qualitative phase, six studies remained.
All six found a positive effect of neuroHAART on neurocognitive function or CSF HIV suppression. Of these six
studies, only two had statistical power of at least 80%.
Conclusions: Studies assessed as using more rigorous methods found that neuroHAART was effective in improving
neurocognitive function and decreasing CSF viral load, but only two of those studies were adequately statistically
powered. Because all of these studies were observational, they represent a less compelling evidence base than
randomised control trials for assessing treatment effect. Therefore, large randomised trials are needed to determine
the robustness of any neuroHAART effect. However, such trials must be longitudinal, include the full spectrum of
HAND, ideally carefully control for co-morbidities, and be based on optimal neuropsychology methods.
Background
The possibility that some antiretroviral drugs with more
efficient Central Nervous System (CNS) penetration as
part of Highly Active Antiretroviral Therapy (HAART)
may be associated with better neurocognitive (NC) func-
tioning and more efficient cerebrospinal fluid (CSF) HIV
RNA suppression than other ARVs has important clini-
cal and therapeutic implications [1]. In this paper, we
will refer to more efficient CNS HAART as
neuroHAART.
First, if true, it indeed means that a non-negligible
number of individuals with HIV-associated neurocogni-
tive disorders (HAND) are not receiving optimal treat-
ment. Without proactive assessment of HAND, the
individuals with asymptomatic neurocognitive impair-
ment (ANI) and Mild Neurocognitive Impairment
(MND) [2], which now represent the greatest proportion
of HAND (as opposed to HIV-associated dementia;
HAD in the pre-HAART era) are likely not to be con-
sidered for a specific therapeutic strategy. A French
study [3] brings support to this potential sub-optimal
* Correspondence: lcysique@unsw.edu.au
1Departments of Neurology and HIV Medicine, St. Vincent’s Hospital, Sydney,
Australia
Full list of author information is available at the end of the article
Cysique et al. BMC Neurology 2011, 11:148
http://www.biomedcentral.com/1471-2377/11/148
© 2011 Cysique et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.treatment scenario. This study found that in the pre-
HAART era, individuals with HAD were preferentially
treated with antiretrovirals with greater CNS penetra-
tion. However, this was still sub-optimal as it used pre-
HAART drugs. They then found that in the HAART
era, the treatment strategy as assessed retrospectively,
did not favour neuroHAART for individuals with HAD,
while ANI and MND were not considered at all.
Second, and perhaps most importantly, there are cur-
rently no HAART guidelines for HAND [4]. While this
topic is hotly debated [5], still an informative review of
the literature has been missing.
Lastly, there is the prospect that some individuals at
risk for HAND may benefit from preventative treatment.
This question is currently being studied in an interna-
tional large-scale trial: http://insight.ccbr.umn.edu/start/
T h ep o s s i b l es u p e r i o re f f i c a c yo fn e u r o H A A R T ,h o w -
ever, remains highly controversial in the HIV research
community because studies have provided conflicting
results. More importantly, the definitions of what consti-
tutes neuroHAART vary (see [1] for review of neuro-
HAART definitions). The underlying premise that the
brain is an HIV sanctuary site less amenable to effective
systemic treatment is itself at the centre of a scientific
debate [6]. However, evidence for the central nervous
system (CNS) being a virological sanctuary site can be
drawn from clinical [7], CSF [8-10] and human neuro-
pathological studies [11,12].
The aim of this review is to better synthesise the
results of existing studies conducted to address the issue
of the potential superior efficacy of neuroHAART on
brain functions and CSF HIVRNA suppression. This
review is based on an innovative staged review strategy
which was designed to overcome study design and neu-
roHAART definition variations. First, each study was
reviewed using a blind quality scoring for the presence
or absence of major design, methodological and analysis
features (adapted from [13]) combined with a non-blind
assessment of appropriate use of demographic and long-
itudinal (practice effect) corrections on neuropsychologi-
cal data, as well as test sensitivity to HAND. Studies
with at least three methodological limitations were
excluded (incidentally retaining studies within the upper
confidence interval limits of the quality scoring distribu-
tion). Remaining studies were then evaluated for statisti-
cal power, that is their ability to detect a significant
difference based on their stated aims. The implications
of the findings are discussed for future research.
Methods
Study selection and data extraction
Individual studies were retrieved via a search of Pubmed
with the following keywords here presented in alphabe-
tical order: antiretroviral, CSF, cognitive functions, CNS,
HAART, HIV RNA, HIV-associated dementia, HIV-
associated neurocognitive disorders, HIV/AIDS, index,
neuropsychological functions, penetrance, penetration.
The following combinations were used: 1. HIV-asso-
ciated dementia and antiretroviral, CNS, penetrance,
penetration, index, HAART, CSF, HIV RNA. 2. HIV-
associated neurocognitive disorders and antiretroviral,
CNS, penetrance, penetration, index, HAART, CSF, HIV
RNA. 3. Neuropsychological functions, HIV/AIDS, and
antiretroviral, CNS, penetrance, penetration, index,
HAART, CSF, HIV RNA. 4. Cognitive functions, and
antiretroviral, CNS, penetrance, penetration, index,
HAART, CSF, HIV RNA.
The following criteria were then used to select studies:
1. Reports had to be conducted in the HAART era
(that is after 1996).
2. Group comparisons had to have subject numbers
of 10 or more; lower numbers provide unstable
effect sizes.
3. Reports had to investigate the effect of more than
o n es i n g l ed r u go na ne x i s t i n gH A A R Tr e g i m e n
because the current review was focused on multiple
ARV agents’ effect.
4. Studies had to not be based on retrospective data
analyses. Some of those studies not only included a
sub-optimal definition of HAND, but also were
prone to systemic biases in the baseline clinical sta-
tus of individuals starting a more or less efficient
neuroHAART regimen [14].
Using these criteria 16 studies were identified and they
are detailed in Table 1. Seven were excluded and their
references are included in additional file 1.
Qualitative analysis
Blinded and non-blinded review for quality scoring
Because the quality (as assessed by statistical power,
sample size, reliability of assessment of HAND, defini-
tions of CNS penetration efficiency (CPE) score, and
neuropsychological methods) of studies varied substan-
tially, we computed a score to rank each study on these
factors. This scoring form was adapted from [13]. The
statistical methods and design used in each study were
reviewed blindly by E.K.W who was provided with a
printed copy of the studies (after removal of authorship
identifiers and without the title, the abstract and the dis-
cussion) and a scoring form (additional file 2). In brief,
we used 15 quality criteria that fell into 5 categories
(Blinded: design, outcomes, subjects, controls, and un-
blinded outcomes). A not-applicable option was pro-
vided for criteria that might not apply for all studies (e.
g., it made no sense to examine whether there were
demographic differences between cases and controls in
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Page 2 of 10Table 1 Review of studies that have assessed the effect of CNS penetrating ARTs on NP performance and/or on CSF
HIV RNA
Author &
date
What Samples HIV
Disease
Design Findings Quality
scoring
> 80%
*
< 80% Quality
scoring
Main factors
POWER
> 80%
Antinori et
al., 2002 [25]
CSF
39%
detectable
viral load
at baseline
75 advanced
HIV+ individuals
37% naive
29 advanced
HIV+ individuals
39%
AIDS
Median
current
CD4: 131
Cross-sectional
Longitudinal
Initiating cART or
new cART/retest
mean: 11 weeks
Indinavir associated with
greater HIV RNA suppression
in the CSF
Greater CSF HIV RNA
suppression with 3 or more
CNS penetrant ARTs
No Clinical groups
heterogeneous
with multiple
types of CNS HIV-
related disorders
IVDU risk factor in
40%
-
Chang et
al., 2003
[26]
NP tests
CSF
97%
detectable
viral load
MRS
33 HIV+
individuals all
ART naïve
19 with HAD
Mean
current
CD4: 182
Longitudinal
3 months follow-
up
NP tests
MRS
Better NP performance in
individuals on 2 CNS
penetrant drugs on 2 NP tests
No correlation between
number of CNS penetrant
ARTs and reduction in MRS
abnormalities.
Yes - No
Cysique et
al., 2004
[27]
NP tests 97 advanced
HIV+ individuals
on long-term
CART (average 5
years)
100% AIDS
Mean
Nadir
CD4: 73
Mean
current
CD4: 369
Cross sectional Better performance in
Learning and memory when
on a CART regimen with = >
3 neuroactive agents in NP
impaired (N = 26)
Yes - No
Cysique et
al, 2006 [28]
NP tests 81 advanced
HIV+ individuals
on long-term
CART (average 5
years)
100% AIDS
Mean
Nadir
CD4: 73
Mean
current
CD4: 385
Longitudinal
Yearly for an
average of 27
months
Improvement on Psychomotor
speed
on a CART regimen with = >
3 neuroactive agents
No Inclusion/
exclusion criteria
not readily
available;
NeuroHAART
definition not
readily available
-
Author &
date
What Samples HIV
Disease
Design Findings Quality
scoring
> 80%
*
< 80% Quality
scoring
Main factors
POWER
> 80%
Cysique et
al. 2009 [29]
NP tests
CSF
85%
detectable
at baseline
37 HIV+
individuals with
mild to
moderate HAND
Initiated on
CART
38% ART naïve
Means
Nadir
CD4 =
106
Baseline
CD4 =
195
AIDS
77%
Longitudinal
Every 12 weeks for
48 weeks
Overall improvement in
cognitive functions with
higher CPE
Yes - No
De Luca et
al., 2002
[30]
CSF
Median
log 10 CSF
HIV RNA:
2.9
95 HIV+
individuals
On cART
50 HIV+
individuals On
cART
Median
current
CD4: 110
Median
current
CD4: 59
Cross-sectional
Longitudinal
Follow-up median
of 7 weeks
Higher number of CNS
penetrant ARTs correlated
with lower CSF HIV RNA
(trend only).
Greater longitudinal decrease
in CSF HIV RNA associated
higher number of CNS
penetrant
No Clinical groups
heterogeneous
with multiple
types of CNS HIV-
related disorders
IVDU risk factor in
30-40%
-
Eggers et
al., 2003
[31]
CSF
80%
detectable
at baseline
40 HIV+
individuals
10 with HIVE
8 with HAD
Median
current
CD4: 60
29%
CDC
stage C
Longitudinal
LP prior and after
cART initiation
Unclear time-frame
No correlation between the
number of CNS penetrant
drugs and slope of CSF viral
decay.
No Definition of
HAND using brief
screens
Clinical groups
heterogeneous
-
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HIV RNA (Continued)
Marra et al.,
2003 [32]
NP tests
CSF
75%
detectable
at baseline
25 HIV+
individuals
HAND baseline
rate?
Mean
current
CD4: 259
Longitudinal
Testing before
CART initiation at 4
& 8 weeks after
Comparison of
regimen
containing AZT &
IDV to other
regimen
Improved on 4 NP tests
associated with VL
suppression in the CSF in ART
naïve (but not 8 weeks)
No significant change in CSF
viral load.
No Small test battery
Unclear inclusion/
exclusion criteria
Unclear baseline
level of NP-
impairment
No adequate
normative data
No practice effect
correction
-
Author &
date
What Samples HIV
Disease
Design Findings Quality
scoring
> 80%
*
< 80% Quality
scoring
Main factors
Marra et al.,
2009 [33]
NP tests
CSF
Median
log 10 CSF
HIV RNA at
baseline:
3.3
101 HIV+
individuals
initiating or
changing cART
Median
CD4: 111
Longitudinal
Follow-up at 24
and 52 weeks
ACTG 736
Odds of suppression of CSF
HIV RNA were higher when
CPE rank was = > 2 (N = 79)
Impaired HIV+ individuals
on a cART with a CPE = >
2 had worse NP
performance over time (N
= 26) on NP 4 tests, but
not 8 NP tests.
No Unclear inclusion/
exclusion criteria
Short NP testing
battery
Lack of education
and racial
correction in NP
tests relevant to
the study
population
-
Letendre et
al., 2004
[34]
CSF
Mean log
10 CSF HIV
RNA at
baseline:
4.1
31 HIV+ with
mild to
moderate HAND
81%
AIDS
Means
nadir
Cd4: 30
Current
CD4: 111
Longitudinal
Testing before &
15 months after
CART initiation
Greater CSF HIV RNA reduction
with higher number of CNS
penetrant ARTs
No Unclear study
time points
No control for
practice effect
Correlational
analyses only
No practice effect
correction
-
Letendre et
al., 2008
[35]
CPE
CSF
17%
detectable
at baseline
467 HIV+
individuals on
cART
389
Undetectable
and 78
Detectable
77%
AIDS
Medians
nadir
CD4: 116
current
CD4: 406
Cross-sectional
Validation of the
CPE index
CPE < 2 associated with an
88%
increase in the odds of
detectable CSF viral load
CPE ranks were associated
with detectable CSF viral loads
with and without treatment
and disease adjustments
Yes - No
Patel et al.,
2009 [36]
Survival
time
2398 HIV+
children
77 incident HIVE
[incidence rate
5.1 cases per
1000 person-
years.
CD4% ≤
15%:
19%
Longitudinal
Median 6.4 years
AACT219/219C
High CNS-penetrating
regimens associated with a
survival benefit (74% reduction
in the risk of death, 95% CI
39-89%) after HIVE diagnosis
compared with low CNS-
penetrating regimens
No Clinical groups
heterogeneity
Clinical diagnoses
as outcome
No NP
assessment
-
Author &
date
What Samples HIV
Disease
Design Findings Quality
scoring
> 80%
*
< 80% Quality
scoring
Main factors
Sacktor et
al., 2001
[37]
NP tests 18 in single in
CSF penetrant
group
55 in multiple
CSF penetrant
group
With
psychomotor
slowing
6-7% HAD
11%-31%
AIDS
Mean
current
CD4:
339-255
Longitudinal
Six annual study
visit
cART initiation
No difference in NP
improvement between 2
groups.
No Unclear inclusion/
exclusion criteria
NeuroHAART
definition not
readily available
Short NP battery
-
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Page 4 of 10observational studies with no control arm). Importantly, a
non-blinded review of the presence or absence of neurop-
sychological cross-sectional norms, longitudinal norms
(correction for practice effect) and validity and sensitivity
of tests used to assess NC performance in HAND (includ-
ing size of the neuropsychological battery) was then per-
formed by a neuropsychologist (L.A.C.). This review was
non-blinded because it sometimes required the explora-
tion of previous papers by the same research team. There-
fore a choice was made that all papers would be treated
equally with a non-blind assessment.
As mentioned above, in some instances, quality cri-
teria were “not applicable” to some included studies. To
account for these cases and still rank the study on a
similar scale, a total percentage score was developed.
This total percentage score was computed based on the
aforementioned criteria and studies were ranked (see
Table 1). A score less than or equal to 80% meant that
a study presented at least three or more significant
methodological limitations. This continuous score was
developed to be more transparent than assessing quality
categories such as “poor”, “medium” or “high” quality
(additional file 3).
Whilst our qualitative analysis necessarily involved
subjectivity, when presented with studies of poor or
v a r i a b l eq u a l i t ys o m es u b j e c t i v ea s s e s s m e n ti sn e e d e dt o
ensure that like is compared with like;aw e l ld e s i g n e d
RCT should ideally not be grouped with a retrospective
observational study in such an analysis. Whilst Finney
argued in a seminal paper on meta-analysis that an
assessment can be purely qualitative when studies are
heterogeneous in nature or provide low quality evidence,
[15] our scoring method enabled us to transparently
identify qualitatively similar studies and analyse them
further to provide some quantitative conclusions.
Quantitative analysis
Power computations
The objective of the power analysis was to determine
the study’s ability to assess its proposed research aims.
Table 1 Review of studies that have assessed the effect of CNS penetrating ARTs on NP performance and/or on CSF
HIV RNA (Continued)
Sevigny et
al., 2004
[38]
Incident
HAD
203 advanced
non-demented
HIV+ individuals
73% on cART
Median
current
CD4: 127
Longitudinal
Median follow-up
of 21 months
36% with incident
HAD
Regimens containing = >
CNS penetrant ARTs was not
associated with time to HAD
No Clinical groups
heterogeneity
Ad hoc analyses
of time to HAD
Time to HAD not
a validated
measure of NP
change
-
Smurzynski
et al., 2011
[39]
NP tests 2636 HIV+
individuals at
least 6 weeks on
cART
Median
current
CD4: 243
Nadir
CD4: 182
Longitudinal
Median follow-up
of 4.7 years
CPE rank score &
ARTs in cART
Neuroscreen: 3 NP
tests
When cART was composed of
more than 3 ARTs there was a
positive association between
CPE and better NP
performance in unadjusted
and adjusted models.
Yes Yes
Tozzi et al.,
2009 [40]
NP tests Patients with (n
= 93) or at risk
for (n = 92) HIV-
associated
neurocognitive
disorders
37%
stage
CDC C
Mean
current
CD4: 292
Nadir
CD4: 181
Cross-sectional
Longitudinal
NP testing before
and after cART
initiation (20
months mean
interval)
Comparison of 2
“neuropenetration”
scores (CPE vs.
numbers)
Higher CPE correlated with
better NP performance at
baseline and follow-up, but
not using the number of
CNS penetrant drugs
Yes - Yes
NB: italicized font: beneficial effect of NeuroHAART on NP performance and or CSF HIV RNA reduction
Regular font: neutral effect of the NeuroHAART,
Bold front: negative effect of NeuroHAART.
ARTs: Antiretrovirals
LP: lumbar puncture
HIVE: HIV encephalopathy
MRS: Magnetic Resonance Spectroscopy
MND: Minor motor Deficits
MSK: Memorial Sloan Kettering
NP: neuropsychological
A score less than or equal to 80% meant that a study presented at least three or more methodological limitations.
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Page 5 of 10Accordingly, we developed the following strategy: the
power computations were conducted [16] using GPo-
wer version 3.1 [17] for the studies with a quality scor-
ing greater than 80%. The power projections were
made for conventionally small, medium and large
effect sizes (namely, 0.20; 0.50 and 0.80) [18]; and were
made separately for cross-sectional and longitudinal
designs and univariate and multivariate designs (see
Figure 1). The studies were then checked against an
“acceptable” criterion: power of 80%; two-tailed with a
p-value less than 0.05. Using this criterion for a med-
ium effect size (d = 0.50), we selected which studies in
the review were conducted with acceptable power,
though it should be acknowledged that the definition
of acceptable power is inherently subjective [19].
Results
The quality scores from the 16 studies were normally
distributed with a mean of 76.6% and a standard devia-
tion of 12.8% (additional file 3). Of the 16 studies ana-
lysed, six had less than three methodological limitations,
and none obtained a quality of 100% which would have
reflected an optimal design for addressing their research
aims (see Table 1). Four of the six studies retained were
longitudinal; all included individuals who had been well
characterised neuropsychologically and clinically to
determine the full HAND spectrum, while using appro-
priate normative data when required. The four retained
longitudinal studies included statistical methods taking
into account the potential practice effect associated with
repeated neuropsychological testing. All these studies
Figure 1 Power projections. The figure provides power projections for four different study designs in order to assess NeuroHAART effect on
neurocognitive or CSF HIVRNA suppression (i.e., panel 1 illustrates a cross-sectional design; panel 2 a longitudinal design; panel 3 an univariate
regression model design, and panel 4 a multi-variable regression model design). The first part of the power projection is dedicated to sample’s
comparisons and the second part to the testing of the magnitude of the neuroHAART effect on neurocognitive functions or CSF HIV RNA. For
each panel, power projections were computed to detect a small, medium and large effect size. In each panel, the six studies found to be of
“appropriate quality” were rated against the power’s projection for their relevant design and arrows indicates the N enrolled for each study. In
addition a red circle in each power panel indicates the criterion against which studies were defined as having “appropriate versus non-
appropriate power” and this was selected for the medium effect size.
Cysique et al. BMC Neurology 2011, 11:148
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Page 6 of 10found a positive effect of NeuroHAART on NC yielding
small to large effect sizes (additional file 4). One cross-
sectional study and one longitudinal study also found
that CSF HIVRNA was more effectively suppressed as a
function of a higher CPE.
Studies’ quality scoring highlights (see also Table 1)
Heterogeneity of study samples
A number of studies included individuals with various
HIV-associated neurological conditions. Others did not
carefully report inclusion or exclusion criteria. A few
studies did not provide enough information to assess
the baseline rate of neuropsychological impairment in
their cohort. Lastly, convenience comparisons were
sometimes used between a sample on and off Neuro-
HAART while these samples differed on a number of
important clinical characteristics.
Insensitive assessment tools in the case of neurocognitive
studies
Among the studies investigating NC functions, five (out
of 11) included either a small number of tests or clinical
scales rather than standard neuropsychological assess-
ment. Others used non-cognitive endpoints such as time
to HAND and survival time, which do not directly
address potential change in NC functions, but only
represent surrogates that are less sensitive to neuropsy-
chological change.
Lack of norms and practice effect correction
One study did not use adequate normative data correc-
tion for demographic factors potentially misclassifying
impairment rate at baseline. Among the neuropsycholo-
gical longitudinal studies, 50% did not correct for
practice.
Assessment time points
One major point in the heterogeneity of the published
study designs was the variation in test retest intervals.
Among studies with higher quality scoring, only one
used a short test retest at 3 months. The four others
used at least a 12 month retest interval.
Studies quantitative analysis highlights (see also Table 1)
Power
Using our criterion for “appropriate power” we found
that two of the six studies with higher quality scoring
were conducted with appropriate power (medium effect
size that is d = .50; 80%, 2-tailed with p = .05). Figure 1
also illustrates which criterion was used for the four dif-
ferent study designs).
Other major issues in all studies
Non-reported p-values or data to compute effect sizes
The majority of studies reported p-values or data allow-
ing effect sizes’ conversion when appropriate. Two
studies did not provide exact p-values or data for their
non-significant findings (see legend for Table 1).
Various definitions of neuroHAART
Studies used various definitions of neuroHAART (see
Table 1) sometimes including less than the conventional
definition for HAART without good rationale (i.e., less
than three ARVs in some comparisons). Seven studies
used a simple continuous aggregate of ARVs with good
penetration. Moreover, five of 16 studies (excluding the
CNS Penetration Effectiveness (CPE) validation study)
have used what has been termed the CPE score. This is
an empirically derived score that is a summed aggregate
of the individual scores for each ARV in a HAART
regimen.
Discussion
Our search criteria identified 16 studies that addressed
the issue of neuroHAART efficacy.
Qualitative analysis of these studies for the presence of
less than three major methodological limitations (which
incidentally corresponded to selecting studies within the
5% upper bound of the Student t distribution) showed
that 37.5% (6 out of the 16) met the criterion for “higher
quality”. The main methodological limitations, which are
relatively common to the field of clinical research in
NeuroAIDS, were clinical heterogeneity of the sample
studied or compared, unclear inclusion/exclusion cri-
teria, insensitivity/brevity of the neuropsychological bat-
tery in 45% of studies, and lack of correction for
practice effect (this was found in 50% of longitudinal
studies). Other less common limitations were lack of
normative correction for baseline demographic factors,
and the definition of neuroHAART not fully described
to allow direct replication.
Among the studies that scored above the quality scor-
i n gc u t - o f f ,i ts h o u l db en o t e dt h a tn o n ea c h i e v e da
100% score. This reflects the practical and scientific
constraints of clinical research studies. One study did
not provide clear enough inclusion/exclusion criteria;
one did not provide a clear neuroHAART definition for
direct replication; one used a medium-size neuropsycho-
logical battery and one a very brief neuropsychological
battery; one included comparison groups with a lack of
clinical homogeneity, and one did not include correction
for practice effect. It should be noted here that the blind
review allowed applying the same strictness to the stu-
dies’ evaluation for all studies.
Moreover, our quantitative analysis on the remaining
six studies which met an adequate quality scoring
showed that two met the criterion for 80% ap r i o r i
power. The advantage of our staged strategy was that
only studies with a higher quality, hence greater com-
parability could be assessed in the quantitative phase.
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methodological limitations and in most studies, lack of
power render the literature difficult to readily interpret
without both the qualitative and quantitative approach
outlined in this paper. In favour of a positive Neuro-
HAART effect are the six studies with higher quality
scoring, however most are underpowered and none
were randomised. Nonetheless, all six controlled for fac-
tors that may have been affected by non-randomization
using multivariate analyses and still yielded results in
favour of a positive neuroHAART effect on NC func-
tions or CSF HIVRNA suppression.
While these results are not definitive they may assist
the clinician in decision making as no negative effect of
NeuroHAART was predominant. It seems reasonable,
therefore, to consider neuroHAART whenever possible
in a patient with HAND, notwithstanding issues of
adherence and resistance to particular ARVs. However,
t h em o s td e f i n i t i v ea n s w e rt ot h ei s s u eo ft h ep o t e n t i a l
superior efficacy of neuroHAART remains randomised
controlled clinical trials conducted in different regions
of the world to provide cumulative evidence.
Limitations of the current qualitative and quantitative
review are that it was based only on published studies
and did not account for any publication bias towards
only reporting positive effects. However, because the
existence of any neuroHAART effect is an area of great
uncertainty in NeuroHIV and HIV/AIDS research, we
contend that a negative finding is of substantial interest
and as likely to lead to a publication as a positive find-
ing. Finally it could be argued that our qualitative phase
should have selected a stricter level of quality. However,
as discussed above, a stricter level of quality would have
excluded almost all studies form the quantitative analy-
sis. Moreover, despite methodological limitations, obser-
vational studies are an important phase of clinical
research, providing preliminary evidence regarding treat-
ment efficacy.
From our analysis of existing studies there are several
key aspects that should be considered in the design of a
potential future trial.
1. A priori power analyses should be conducted for the
ability to detect at least a medium effect size. This
implies that a future trial should include at least 100
subjects in each arm (see also Figure 1; multivariate
graph). This also takes into account the full HAND
spectrum including at least mild neurocognitive disorder
(MND) [2] and that adequate power is needed to detect
a relatively small effect (the treatment effect) in indivi-
duals who are not demented, but do have neurocogni-
tive difficulties.
2. Adequate outcome measures should be selected.
Even if a brief assessment is selected, it should be tar-
geted to include tests of psychomotor speed, working
memory as well as learning and memory to have a
wider range of potential benefit from neuroHAART
[20]. Related to this issue, and because of the high com-
plexity of the neuropsychological data in this type of
study, the inclusion of a senior neuropsychologist in the
research team is essential. Moreover, the use of neuro/
psychology graduates for a high quality and standard
administration of neuropsychological instruments
including computerised battery is highly recommended.
Because the NC measure represents the main outcome of
those studies, special care in the data collection and data
management should be a basic requirement. This will
reduce measurement error and systematic biases that
are likely with a poorly trained staff or staff who do not
have the basic clinical skills to examine patients with
cognitive impairment.
3. Adequate sampling: the study should carefully con-
sider what types of patients are to be included with
clear inclusion and exclusion criteria. Principally, the
current HAART status and HAART duration should be
considered, (See [21] for extensive consideration on this
issue). Lastly, if the study includes a test of HIV RNA
change, a baseline level of detection may be set as an
inclusion criterion to improve the homogeneity in each
arm on this aspect. Other aspects that may be consid-
ered to improve arm homogeneity are HIV duration,
nadir CD4, and previous HAART history.
4 .A d e q u a t es t u d yt i m ep o i n t s :t h es t u d ys h o u l db e
longitudinal and select an early follow-up to detect HIV
RNA changes in the CSF and plasma as well as NC
change (between 4 and 7 weeks after treatment initia-
tion) and, a longer follow-up ideally at about 48 weeks,
to detect long-term NC change. The risk of a shorter
term trial is to produce negative or neutral findings
when actually a positive effect is at play [21].
5. Adequate analytical strategies: in a randomised trial,
which by design minimize systematic biases between
treatment arms on the outcome measures, extra consid-
eration in the use of neuropsychological normative data
to determine baseline impairment rate is needed. In
some instances adaptive randomization may offer a flex-
ible solution (see [22] for further discussion on this
issue).
5. We would recommend the use of the CPE score
pending improved definitions and over older definitions.
This would allow planning preliminary analyses with the
version of a current CPE at the time of enrolment in
future clinical trials. Uniform use of the CPE score
would make direct comparisons of the regimens used in
different studies easier and enable a larger evidence base
to define the most effective neuroHAART regimens to
be compiled. In the future definitions, the role of a
potentially impaired BBB should also be considered [23].
Also, the adverse effect of some ARVs on the cardio-
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Page 8 of 10vascular system would need to be taken into account in
the new version of a CPE score as they have been asso-
ciated with NC impairment in the HIV population [24].
Conclusions
Studies assessed as using more rigorous methods found
that neuroHAART was effective in improving neurocog-
nitive function and decreasing CSF viral load, but only
two of those studies were adequately statistically pow-
ered. Because all of these studies were observational,
they represent a less compelling evidence base than ran-
domised control trials for assessing treatment effect.
Therefore, large randomised trials are needed to deter-
mine the robustness of neuroHAART effect. However,
such trials must be longitudinal, include the full spec-
trum of HAND, ideally carefully control for co-morbid-
ities and be based on optimal neuropsychology methods.
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